# Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

> **NCT04138719** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 520 (estimated)

## Conditions studied

- Breast Cancer
- Triple-negative Breast Cancer
- Nab-paclitaxel

## Interventions

- **DRUG:** Nab-paclitaxel + Carboplatin
- **DRUG:** Nab-paclitaxel + Epirubicin

## Key facts

- **NCT ID:** NCT04138719
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-11-20
- **Primary completion:** 2026-10-20
- **Final completion:** 2028-06-20
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138719, "Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04138719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*